Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and lowers the price target from $10 to $8.
Barrington Research Maintains Outperform on Lifecore Biomedical, Lowers Price Target to $8
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.